Ascentage Pharma Group International

AAPG | NASDAQ

Price Alert Chart Builder DCF Calculator

$15.86

+$0.80 (+5.31%)

At close: Sep 21, 2026, 4:00 PM ET

$15.82

-$0.04 (-0.25%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $1.4B

Enterprise Value $10.2B

Beta 0.66

Average Volume 9.81K

Shares Outstanding (Diluted) 93.31M

Shares Change YoY 26.09%

Institutional Ownership 0.03%

Exchange NASDAQ

ISIN US04390B1052

Price Performance

Price Change 1M -5.8%

Price Change 3M -6.8%

Price Change 6M -29.1%

Price Change YTD -39.9%

Price Change 1Y -58.6%

Price Change 3Y -8.8%

Price Change 5Y -8.8%

1M CAGR (ann.) -11.9%

1Y CAGR (ann.) -61.3%

5Y CAGR (ann.) N/A

All-Time CAGR -8.3%

Valuation

PE Ratio -7.11

Forward PE 8.28

PEG Ratio 0.62

Forward PEG 0.10

PS Ratio 16.29

Forward PS 5.20

PB Ratio 17.97

P/FCF Ratio -7.37

P/Adj. FCF Ratio -7.37

P/OCF Ratio -7.50

EV/Sales 16.12

EV/EBIT -7.37

EV/EBITDA -7.85

EV/FCF -7.29

Earnings Yield -14.7%

FCF Yield -14.2%

Adj. FCF Yield -14.2%

Financial Health

Net Debt ¥184.95M

Total Debt ¥2.1B

Cash & Short-Term Investments ¥1.9B

Total Assets ¥3.24B

Current Ratio 1.22

Quick Ratio 1.18

Debt / Equity Ratio 3.76

Debt / EBITDA -1.61

Debt / FCF -1.50

OCF / Debt -0.66

Interest Coverage -26.48

Altman Z-Score -2.32

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 81.6%

Operating Profit Margin -218.8%

EBITDA Margin -205.4%

Net Profit Margin -228.7%

FCF Margin -221.1%

Adj. FCF Margin -221.1%

SBC / Revenue 0.0%

SBC Impact (per share) N/A

Returns

Return on Assets -44.6%

Return on Equity -153.8%

Return on Invested Capital -48.9%

Return on Capital Employed -102.0%

Return on Tangible Assets -45.5%

Historical Growth (CAGR)

Revenue CAGR 3Y 260.8%

Revenue CAGR 5Y 177.7%

Revenue CAGR 10Y N/A

EPS CAGR 3Y 74.5%

EPS CAGR 5Y 19.4%

EPS CAGR 10Y N/A

FCF CAGR 3Y -20.9%

FCF CAGR 5Y -30.8%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 1

EPS Growth Next 3Y 41.5%

Revenue Growth Next 3Y 109.0%

Earnings Date Mar 30, 2027

EPS Estimate (next Q) -$0.05

EPS Growth Est (next Q) -49.7%

Revenue Est (next Q) $7.26M

Revenue Growth Est (next Q) -1.8%

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $40

Price Target Upside 152.2%

Cash Flow

Operating Cash Flow ¥-1.38B

Free Cash Flow ¥-1.4B

Adj. Free Cash Flow ¥-1.4B

FCF Per Share -$15

OCF Per Share -$14.79

OCF/S Ratio -218.0%

Income Statement

Revenue ¥633.01M

Gross Profit ¥516.31M

Operating Income ¥-1.38B

EBITDA ¥-1.3B

Net Income ¥-1.45B

EPS (Diluted) -$15.60

Revenue / Employee $825.31K

Profit / Employee $-1.89M

Employees 767